|
Can we think of competing-event as another form of non-event in terms of utility?
|
|
0
|
1079
|
April 21, 2024
|
|
Is Lithium Equivalent to Lecanemab in Slowing cognitive decline in Alzheimer's Disease?
|
|
0
|
1122
|
February 23, 2024
|
|
Review of Trial at the Center of the Firestorm Over Early Connection of Patients to Ventilators during the Pandemic
|
|
34
|
5695
|
February 16, 2024
|
|
Does subtracting/or not, the mean-rank in Wilcoxon-Mann-Whitney make any difference?
|
|
4
|
1224
|
February 1, 2024
|
|
Ranked analysis of ANCOVA
|
|
7
|
3237
|
January 21, 2024
|
|
AUC of each subgroup is smaller than overall AUC
|
|
7
|
5737
|
November 13, 2023
|
|
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times
|
|
2
|
1733
|
October 3, 2023
|
|
About the interpret category
|
|
1
|
3424
|
October 3, 2023
|
|
Comparing "all active dose" to placebo - do we treat "all active dose" as one group or separate groups?
|
|
2
|
1108
|
September 4, 2023
|
|
Guidance of analysis of longitudinal patient reported outcomes w.r.t Joint models
|
|
4
|
1733
|
August 29, 2023
|
|
Design of Experiments in Economics vs Medicine: a Decision Theory POV
|
|
6
|
2853
|
July 27, 2023
|
|
Inferences from summary data - without seeing the data for a Cox PH model, do chi square tests tell us anything?
|
|
5
|
670
|
July 24, 2023
|
|
Case-control study with and corresponding subgroup
|
|
2
|
1003
|
July 20, 2023
|
|
Impact of Model Intercepts on Ordinal Logistic Regression Outcome
|
|
7
|
2769
|
June 22, 2023
|
|
P values and small sample size
|
|
6
|
1499
|
June 20, 2023
|
|
Minimum PPV/NPV values to reach positive net benefit and net benefit avoided
|
|
10
|
1819
|
June 12, 2023
|
|
Outlier detection
|
|
3
|
1881
|
May 11, 2023
|
|
HR really close to 1 but significant - how to interpret and report?
|
|
9
|
2283
|
April 25, 2023
|
|
FDA "Bad Habits"
|
|
7
|
2560
|
March 4, 2023
|
|
Advice regarding a Directed Acyclic Graph and further analysis Plan
|
|
7
|
2460
|
January 22, 2023
|
|
R package to present summary results from many different mixed effects models
|
|
3
|
1589
|
December 28, 2022
|
|
Interpretation of subject-specific effect in a cross-over study
|
|
5
|
4163
|
November 28, 2022
|
|
Generalized Additive Models with R gam
|
|
1
|
2154
|
November 22, 2022
|
|
Information, Evidence, and Statistics for critical research appraisal
|
|
17
|
4040
|
November 21, 2022
|
|
Categorization of continuous outcome and odds ratio
|
|
2
|
1035
|
November 8, 2022
|
|
Interactions and random error
|
|
24
|
12234
|
October 20, 2022
|
|
Statistics Applied Using Threshold Science Fails to Deliver Progression Toward Truth
|
|
2
|
3408
|
September 23, 2021
|
|
Quality of remdesivir trials
|
|
54
|
20622
|
October 5, 2022
|
|
Between Subjects Variance and Within Subjects Variance in ICC
|
|
2
|
3044
|
September 25, 2022
|
|
Could cardiovescular risk nomogram be supirior than the Framingham Risk Score? If so, what could be the reasons?
|
|
0
|
1249
|
September 20, 2022
|